Acute Myeloid Leukaemia (AML) is a genetically, biologically and clinically heterogeneous set of diseases, which are characterised by an increased growth of abnormal myeloid progenitor cells within the bone marrow (BM). Ex-vivo AML exhibits a high level of spontaneous apoptosis. Furthermore, relapse for patients achieving remission occurs from minimal residual disease harboured within the BM microenvironment. Taken together, these observations illustrate the importance of the BM microenvironment in sustaining AML. While significant progress has been made elaborating the small-scale genetic mutations and larger-scale chromosomal translocations that contribute to the development of AML and its prognosis in response to treatment, less is understood about the complex microenvironment of the BM, which is known to be a key player in the pathogenesis of the disease. As we look towards future therapies, the consideration that the BM microenvironment is uniquely important as a niche for AML -coupled with the idea that leukaemic blasts are more likely to be genetically unstable and therefore evolve resistance to conventional chemotherapies -make the functions of the non-malignant cells of the BM attractive targets for therapy. In this review, we discuss the microanatomy of the BM and provide an overview of the evidence supporting the role of the BM microenvironment in creating conditions conducive to the survival and proliferation of AML blasts. Ultimately, we examine the therapeutic potential of uncoupling AML from the BM microenvironment.
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Introduction
The survival of patients with Acute Myeloid Leukaemia (AML) is presently poor. Twothirds of younger adults and 90% of older adults die of their disease 1 . Even in patients who achieve remission with chemotherapy, relapse is common and occurs from minimal residual disease sequestered in protective niches in the bone marrow (BM) microenvironment.
The malignant blasts that form the AML tumour are presently understood to represent a variety of clinically, morphologically, genetically and epigenetically heterogeneous tumours collectively grouped under the classification of AML [2] [3] [4] [5] . Even within individual patients, AML is now recognised as a number of distinct sub-clones of the disease, 3 and that these sub-clones evolve within patients as the disease is treated leading to potential relapse and progression.
Despite this inter-and intra-tumour heterogeneity, AML clones share many fundamental features. Clinically, these tumours are mitotically highly active, progressing rapidly within the patient. Historically, they have been clinically treated in a similar way (with the exception of acute pro-myelocytic leukaemia). Presently, 
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a subpopulation of AML cells that have long-term repopulating potential, reside in the BM microenvironment and harbour one or more of the oncogenic mutations driving tumourigenesis. Relapse from AML is common and in such patients the cause of leukemic relapse is primarily due to remnant LSCs in the BM following chemotherapy. Leukaemia like most haematological malignancies, can mobilise from bone marrow to blood and the lymphatic system. It's also interesting to note that LICs can also be found in other sites including skin, the central nervous system (CNS) and other organs. 6, 7 .
Accordingly, as all AML are dependent on the BM microenvironment, it has been hypothesised that better patient outcomes may come from novel treatment strategies derived from improved understanding of the biology of AML within the BM microenvironment 8 . Importantly, these treatments could be widely applicable to patients with AML across a spectrum of genetic subtypes.
Acute lymphoblastic leukemia (ALL), (another haematological malignancy of a heterogeneous nature, characterised by B-cell and T-cell progenitors) has also been studied in detail for its dependence on the BM microenvironement. While the survival outcomes of paediatric cases of this disease have greatly improved in the last six years, adult cases still carry a severe prognosis 9, 10 . Much like AML, relapses are attributed to the minimal residual disease of a pool of LIC in dormancy which are unaffected by chemotherapies, which target cycling cells. Various interactions between ALL cells and the microenvironment have been implicated in the progression of this disease; one of the most widely studied interactions is that of the BM fibroblasts and the ALL wherein the BM fibroblasts provide better support and survival for the B-cell ALL lineage 11 .
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In this review, we will highlight the fundamental importance of the BM in normal human haematopoiesis and will further investigate the key role(s) of the cell types therein in providing an environment that contributes to the survival, growth and migration of AML cells. The potential for inhibitory measures against the activity of these non-cancerous BM cells as a means for targeting AML survival will also be explored.
The bone marrow microenvironment and haematopoiesis
The BM is a soft viscous tissue that occupies cavities within the bone 12 . It is comprised of blood vessels and a heterogeneous population of cells that are either directly involved in the BM's primary function of haematopoiesis, or act in support of haematopoietic cell function via the cell types surrounding the haematopoietic cells.
These supporting cells in the BM all contribute to the stimuli required for regulating normal haematopoiesis ( 
A C C E P T E D M A N U S C R I P T
redefined them more stringently, based on in vivo differentiation capability, as skeletal stem cells (SSC) 14, 15 . These cells are found on the surface of the blood vessels of the bone marrow (sinusoids) (Figure 1 Due to the compartmental and heterogeneous nature of its stromal system, the BM is recognised as an organ with two separate yet co-operative systems exhibiting functional co-dependence: the haematopoietic tissue system and its associated supporting stromal tissue system. Originally, much interest was focused on the supporting nature of the stromal system and its contribution to haematopoiesis;
however, recent studies have brought to light the unanticipated differentiation potential of stromal cells into special cell types that are phenotypically distinct from cells from the tissue of origin, an attribute termed 'transgermal plasticity' 17 The identification of this characteristic poses an exciting potential in terms of its manipulation for therapeutic applications. Plasticity of BM stromal cells could hold the key in identifying the switch from normal to malignancy-associated stromal cells and thereby identify a new field of therapeutic strategies for BM malignancies. A C C E P T E D M A N U S C R I P T 27, 28 . The heterogeneous nature of HSCs has given rise to speculation that there could be specialised niches for particular types of HSCs and their progeny within each class of niche 29 . inducing and mediating pro-inflammatory responses, has also been implicated in BMSC change with IL-17 signalling-related genes being over-expressed 30, 47 . Indeed, the therapeutic relevance of BMSCs has been demonstrated by several studies that
show that co-culture of cancer-associated BMSCs with cancer cells induces proliferation and confers drug resistance [48] [49] [50] . This occurs either through intercellular contact or via the secretion of soluble factors 51, 52 . Evidence is accumulating that such alterations may also be relevant to AML, with one of the first studies to examine this demonstrating that direct cellular contact between AML blasts and adherent long-term stroma significantly decreased apoptosis of AML blasts 
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Fibroblasts
The requirement of fibroblasts in AML progression was demonstrated upon coculture of AML blasts with normal BMSCs and two fibroblast lines (HLF1 and Hs27), which the latter were partitioned by a semi-permeable membrane. In the absence of fibroblasts, the AML cells exhibited reduced proliferation, a reduced ability to evade apoptosis and lower levels of IL-8 43 . This suggests that contact between fibroblasts ACCEPTED MANUSCRIPT Osteoblasts have been the subject of a direct study in AML wherein immunocompetent mouse models were demonstrated to have reduced levels of osteocalcin, a secretary factor that promotes bone formation 75 . This phenomenon was observed in the absence of a substantial elevation in osteoclast numbers suggesting that unlike in myeloma, the osteoblastic arm in AML is of more importance than the osteoclastic aspect.
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Adipocytes
Adipocytes are MSC derivatives and make up the majority of yellow marrow, which has been observed to expand with age. The abundance and proximity of fat cells to the leukaemic core coupled with work in other tumour types [76] [77] [78] has led to the hypothesis that such cells may well be involved in the deregulation of cellular energetics that is a hallmark of cancer. Physiologically, obesity is associated with poor clinical outcomes in leukemic patients 79 suggesting that in the context of cancer, adipose tissue may be a contributing factor to treatment resistance and relapse. In the context of haematology, Han et al. showed that adipose tissue can act as a reservoir for hematopoietic stem and progenitor cells 80 which supports the above notion that adipose tissue contributes to cancer protection and disease relapse. The proinflammatory element of leukaemia associated adipose tissue has been identified as a lipolysis-stimulating factor that contributes to adipose tissue atrophy in cancer 81, 82 . Lipolysis in adipocytes and fatty acid oxidation in AML cells
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were the processes discovered to be underlying this phenomenon that has been described as a "metabolic symbiosis" 77 . One recent investigation into the role of adipocytes and free fatty acids in AML has uncovered that free fatty acids from BM adipocytes are able to activate a transcriptional programme that has been correlated with AML cell survival 83 . This investigation also reported fatty acid oxidationdependent metabolism of the AML cell line U937, when co-cultured with MSC- Several studies have shown that adipocytes promote resistance of cancer cells to conventional chemotherapies 85, 86 . One study in particular has shown that adipocytes confer breast cancer cell resistance to antibody-dependent cellular cytotoxicity by 
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these cells to be of significance for the collective retention of leukaemic blasts within the bone marrow 91 and targeting CXCR4 has been shown to upset migration and retention in the bone marrow, thus making it more susceptible to cytotoxic therapies 59, 92 . Furthermore, these cells also express adipocyte-associated PPARγ and osteoblast differentiation-associated transcription factor RUNX2 and Osterix, the disruption of which significantly impacts the number of HSPCs and the B cell and erythroid progenitors. The abundant CXCL12 release from these cells and the role of their differentiating capacity along with the release of various lineage dependant cytokines make these cells viable candidates for targeting factors crucial for leukemic blast retention and migration.
Sympathetic Neural cells
It has long been known that the arterioles that compose the BM microvasculature are innervated by the sympathetic nervous system (SNS) 93 . Accordingly, for many years the function of the SNS within the BM context was believed to be associated with the BM cell mobility 94 . Over 30 years ago, a study in which the BM was denervated produced an increase in the number leukocytes circulating in the peripheral blood Another BM microenvironment-linked hallmark with potential as a target in AML is angiogenesis, which is promoted to facilitate the continuous delivery of oxygen, nutrients and growth factors to the ever-expanding population of malignant cells.
Inhibiting angiogenesis has been conducted using a plethora of approaches, which include tyrosine kinase inhibitors, antibodies that neutralise VEGF receptors and other novel drugs such as statins which may indirectly affect the VEGF pathway [120] [121] [122] . Bevacizumab -which has been approved for the treatment of solid tumours -is a monoclonal antibody that binds to a VEGF isoform and blocks it from binding to its The capacity to invade and metastasise is a unique feature of malignant tumours. To achieve this, tumour cells enlist a variety of mechanisms including chemotaxis and adhesion. Chemokine molecules such as CXCR4, adhesion molecules such as CD44 and VLA4, and integrin are candidate targets of the BM microenvironment that have been shown to interact with the LSC niche and allow tumour migration 125, 126 .
Using a CXCR4 antagonist, AMD3100, studies have shown an elevated white blood cell count as well as mobilisation of leukaemic blasts in the peripheral blood where they can be subjected to the cytotoxicity of chemotherapeutic drugs 106, 107 . Moreover, work in our laboratory shows in vitro that the BTK inhibitor, ibrutinib, inhibits AML adhesion and migration to BMSC, hence the initiation of clinical trials of ibrutinib in AML 92, 127 . Although these approaches have yet to be fully explored, the promise of an effective and durable response necessitates further study analysing the relationship between AML and its microenvironment. Table 3 provides a summary of potential inhibitors of these identified interactions.
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Summary
Understanding the BM niches, their constituents and the mechanisms at play may hold the key to the development of methods/treatments that can directly affect the ability of LSCs to drive malignancy and avoid therapeutic-mediated destruction.
Although systemic therapeutic approaches generally revolve around the direct elimination of malignant stem or progenitor cells, recent studies have shown that targeting abnormalities of the BM may have value 128 . Studies into how migration of quiescent HPSCs from the osteoblastic niche to the vascular niche wherein they acquire the ability to proliferate and differentiate may provide the key to the development of novel therapeutic approaches in the future.
Practice Points
 Clinical out-comes and prognosis in the aging population suffering from AML is poor as medical co-morbidities as well as a reduced haematopoietic reserve within the aging bone marrow present limiting factors.
 Patient relapse following remission is due to minimal residual disease harboured within the bone marrow which demonstrates the importance the leukaemic BM microenvironment in the retention and protection of this disease.
 Non-haematopoietic component of the bone marrow contributes to several functions such as migration, adhesion, metabolism and differentiation.
Research Agenda
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A C C E P T E D M A N U S C R I P T  Dissection of the multi-faceted role played by the BMSC lineages and their non-malignant counterparts in the survival and regulation of AML.
 The genetic differences between the leukaemic and non-leukaemic BMSC may identify potential biomarkers that play a role in resistance and other cellular functions enhanced by the BM microenvironment.
 Targeting the BM microenvironment to limit blast malignancy and metastasis without non-selective destruction of haematopoietic tissue is a more attractive therapeutic strategy in both young and old AML populations.
Conflict of Interest
S.A.R. receives funding from Infinity Pharmaceuticals.
